MMP-9 Expression in Permanent Mature Teeth With Symptomatic Pulpitis

Not Applicable

Completed

• Conditions: Pulpitis
• Interventions: Procedure: Coronal pulpotomy

• Registration Number: NCT03807674
• Lead Sponsor: Eglė Gvazdaitytė

Brief Summary

Matrix metallopeptidase-9 (MMP-9) expression was compared in healthy and inflamed pulp and the outcome of coronal pulpotomy in teeth with symptomatic pulpitis was assessed. After procedure blood samples were examined using Elisa kit.

Detailed Description

Introduction: Widely used diagnostic tests do not provide information to distinguish the pulp inflammation stage while improvement of materials, techniques and vital pulp therapy have received a wider acceptance in symptomatic pulpitis treatment. The aim of this clinical study was to compare MMP-9 expression in healthy and inflamed pulp and to assess the short-term outcome of coronal pulpotomy in mature permanent teeth with symptomatic pulpitis.

Methods: Patients diagnosed with symptomatic pulpitis were included in this clinical study. Coronal pulpotomy was performed using calcium-silicate based material and blood samples were taken. Initial and postoperative pain was recorded by Heft-Parker visual analog scale at 24 hours and 72 hours after the procedure. In control group teeth with healthy pulp were used. During follow-up visits after three and six-months, patients were examined clinically and radiographically. The ELISA kit was used to determine the levels of MMP-9 in inflamed and healthy coronal pulp tissue.

Study Timeline

• Study Start: 2017-03-27
• Primary Completion: 2017-07-15
• Study Completion: 2018-02-11
• Study First Submitted: 2018-11-19
• Status Verified: 2019-01
• Study First Submitted QC: 2019-01-14
• Last Update Submitted: 2019-01-14
• Study First Posted: 2019-01-17
• Last Update Posted: 2019-01-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Teeth diagnosed with symptomatic pulpitis
• Patients who did not use any NSAIDs before the treatment
• Positive cold test of investigated teeth
• Clinically dental caries in contact with pulp chamber
• Permanent teeth with radiographically closed root apex

Exclusion Criteria

• Patients who refuse to participate in the study
• Medically compromised patients (with immunosuppressive/systemic diseases, patients on medications)
• Teeth with periapical radiolucency or clinical signs of apical periodontitis
• Periodontological compromised teeth (probing depth ≥4mm)
• Internal/external root resorption in periapical radiograph
• Pulp chamber and/or root canal calcification in periapical radiograph
• Teeth with unrestorable crown
• Teeth with a negative response to cold test

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control group - Healthy teeth	Coronal pulpotomy	Patients with clinically healthy third molar or premolar teeth with indications for extraction; no clinical signs of pulpitis, no caries, no indications for the replacement of an old filling that is 1 mm from the pulp space as determined on the radiograph; a normal response to the cold test, and no apical radiolucency on the radiograph. For teeth of this group coronal pulpotomy was applied.
Test group - Teeth with pulpitis	Coronal pulpotomy	Patients with symptomatic pulpitis resulting from caries; tooth pain defined as sharp, dull, localized or diffuse; pain at night; a symptomatic tooth with a positive response to the cold test and lingering pain; intermittent or continuous episodes of spontaneous pain (with no external stimulus) that could last from a few minutes up to a few hours; no apical radiolucency on the radiograph. For teeth of this group coronal pulpotomy was applied.

Primary Outcome Measures

Name	Time	Method
MMP-9 amount measurement using ELISA kit	All samples were measured in one time (during 12 hours)	The MMP-9 amount in the pulp blood samples was measured using the MMP-9 Human ELISA Kit. The measurement procedure was followed according to the manufacturer's instructions. The anti-MMP-9 polyclonal antibody was pre-coated on 96-well plates. Blood samples and a biotin-conjugated antibody were added to the wells supplemented with Avidin-Biotin-Peroxidase Complex and 3,3',5,5'-tetramethylbenzidine in a mildly acidic buffer. A blue-colored product was produced and turned to yellow after an acidic stop solution was added. The intensity of the color yellow was proportional to the MMP-9 amount bound on the plate. The optical density absorbance was measured spectrophotometrically at 450nm in a microplate reader and the concentration of MMP-9 was calculated. For the expression of MMP-9 concentrations in the samples, a standard curve was used.

Trial Locations

Locations (1)

Lithuanian University of Health Science; 🇱🇹 Kaunas, Lithuania